Most normal cells will undergo a programmed form of rapid cell death (apoptosis) when critical functions are altered. Activated oncogenes can cause those cells designated for apoptosis to survive and proliferate instead. Most oncogenes require an additional step, such as mutations in another gene, or environmental factors, such as viral infection, to cause cancer. Since the 1970s, dozens of oncogenes have been identified in human cancer. Many cancer drugs target the proteins encoded by oncogenes.
The first theory of oncogenes was given by Danish physicist Niels Henrik Arley around 1950, but was rejected by contemporaries as nonsense. Later on the term "oncogene" was rediscovered in 1969 by National Cancer Institute scientists George Todaro and Robert Heubner.
The first confirmed oncogene was discovered in 1970 and was termed src (pronounced sarc as in sarcoma). Src was in fact first discovered as an oncogene in a chicken retrovirus. Experiments performed by Dr. G. Steve Martin of the University of California, Berkeley demonstrated that the Src was indeed the oncogene of the virus. The first nucleotide sequence of v-src was sequenced in 1980 by A.P. Czernilofsky et al.
In 1976 Drs. Dominique Stehelin, J. Michael Bishop and Harold E. Varmus of the University of California, San Francisco demonstrated that oncogenes were activated proto-oncogenes, found in many organisms including humans. For this discovery, proving Todaro and Heubner's "oncogene theory", Bishop and Varmus were awarded the Nobel Prize in Physiology or Medicine in 1989.
The resultant protein encoded by an oncogene is termed oncoprotein. Oncogenes play an important role in the regulation or synthesis of proteins linked to tumorigenic cell growth. Some oncoproteins are accepted and used as tumor markers.
A proto-oncogene is a normal gene that could become an oncogene due to mutations or increased expression. Proto-oncogenes code for proteins that help to regulate cell growth and differentiation. Proto-oncogenes are often involved in signal transduction and execution of mitogenic signals, usually through their protein products. Upon acquiring an activating mutation, a proto-oncogene becomes a tumor-inducing agent, an oncogene. Examples of proto-oncogenes include RAS, WNT, MYC, ERK, and TRK. The MYC gene is implicated in Burkitt's Lymphoma, which starts when a chromosomal translocation moves an enhancer sequence within the vicinity of the MYC gene. The MYC gene codes for widely used transcription factors. When the enhancer sequence is wrongly placed, these transcription factors are produced at much higher rates. Another example of an oncogene is the Bcr-Abl gene found on the Philadelphia Chromosome, a piece of genetic material seen in Chronic Myelogenous Leukemia caused by the translocation of pieces from chromosomes 9 and 22. Bcr-Abl codes for a tyrosine kinase, which is constitutively active, leading to uncontrolled cell proliferation. (More information about the Philadelphia Chromosome below)
The proto-oncogene can become an oncogene by a relatively small modification of its original function. There are three basic methods of activation:
- A mutation within a proto-oncogene, or within a regulatory region (for example the promoter region), can cause a change in the protein structure, causing
- An increase in the amount of a certain protein (protein concentration), caused by
- A chromosomal translocation (another type of chromosome abnormality)
- There are 2 different types of chromosomal translocations that can occur:
- translocation events which relocate a proto-oncogene to a new chromosomal site that leads to higher expression
- translocation events that lead to a fusion between a proto-oncogene and a 2nd gene (this creates a fusion protein with increased cancerous/oncogenic activity)
- the expression of a constitutively active hybrid protein. This type of mutation in a dividing stem cell in the bone marrow leads to adult leukemia
- Philadelphia Chromosome is an example of this type of translocation event. This chromosome was discovered in 1960 by Peter Nowell and David Hungerford, and it is a fusion of parts of DNA from chromosome 22 and chromosome 9. The broken end of chromosome 22 contains the "BCR" gene, which fuses with a fragment of chromosome 9 that contains the "ABL1" gene. When these two chromosome fragments fuse the genes also fuse creating a new gene: "BCR-ABL". This fused gene encodes for a protein that displays high protein tyrosine kinase activity (this activity is due to the "ABL1" half of the protein). The unregulated expression of this protein activates other proteins that are involved in cell cycle and cell division which can cause a cell to grow and divide uncontrollably (the cell becomes cancerous). As a result, the Philadelphia Chromosome is associated with Chronic Myelogenous Leukemia (as mentioned before) as well as other forms of Leukemia.
The expression of oncogenes can be regulated by microRNAs (miRNAs), small RNAs 21-25 nucleotides in length that control gene expression by downregulating them. Mutations in such microRNAs (known as oncomirs) can lead to activation of oncogenes. Antisense messenger RNAs could theoretically be used to block the effects of oncogenes.
There are several systems for classifying oncogenes, but there is not yet a widely accepted standard. They are sometimes grouped both spatially (moving from outside the cell inwards) and chronologically (parallelling the "normal" process of signal transduction). There are several categories that are commonly used:
|Growth factors, or mitogens||c-Sis||glioblastomas, fibrosarcomas, osteosarcomas, breast carcinomas, and melanomas||induces cell proliferation.|
|Receptor tyrosine kinases||epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), HER2/neu||Breast cancer, gastrointestinal stromal tumours, non-small-cell lung cancer and pancreatic cancer||transduce signals for cell growth and differentiation.|
|Cytoplasmic tyrosine kinases||Src-family, Syk-ZAP-70 family, and BTK family of tyrosine kinases, the Abl gene in CML - Philadelphia chromosome||colorectal and breast cancers, melanomas, ovarian cancers, gastric cancers, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers||mediate the responses to, and the activation receptors of cell proliferation, migration, differentiation, and survival|
|Cytoplasmic Serine/threonine kinases and their regulatory subunits||Raf kinase, and cyclin-dependent kinases (through overexpression).||malignant melanoma, papillary thyroid cancer, colorectal cancer, and ovarian cancer||Involved in organism development, cell cycle regulation, cell proliferation, differentiation, cells survival, and apoptosis|
|Regulatory GTPases||Ras protein||adenocarcinomas of the pancreas and colon, thyroid tumors, and myeloid leukemia||involved in signalling a major pathway leading to cell proliferation.|
|Transcription factors||myc gene||malignant T-cell lymphomas and acute myleoid leukemias, breast cancer, pancreatic cancer, retinoblastoma, and small cell lung cancer||-They regulate transcription of genes that induce cell proliferation.|
More detailed information for the above Table:
- Growth factors are usually secreted by either specialized or not specialized cells to induce cell proliferation in themselves, nearby cells, or distant cells. An oncogene may cause a cell to secrete growth factors even though it does not normally do so. It will thereby induce its own uncontrolled proliferation (autocrine loop), and proliferation of neighboring cells. It may also cause production of growth hormones in other parts of the body.
- Receptor tyrosine kinases add phosphate groups to other proteins to turn them on or off. Receptor kinases add phosphate groups to receptor proteins at the surface of the cell (which receive protein signals from outside the cell and transmit them to the inside of the cell). Tyrosine kinases add phosphate groups to the amino acid tyrosine in the target protein. They can cause cancer by turning the receptor permanently on (constitutively), even without signals from outside the cell.
- Ras is a small GTPase that hydrolyses GTP into GDP and phosphate. Ras is activated by growth factor signaling (i.e., EGF, TGFbeta) and acting like a binary switch (on/off) in growth signaling pathways. Downstream effectors of Ras include three mitogen-activated protein kinases Raf a MAP Kinase Kinase Kinase (MAPKKK), MEK a MAP Kinase Kinase (MAPKK), and ERK a MAP Kinase(MAPK), which in turn regulate genes that mediate cell proliferation.
- Anticancer gene
- Tumor suppressor gene
- Genetic predisposition
- Quantitative trait locus
- Genetic susceptibility
- Wilbur, Beth, editor. The World of the Cell, Becker, W.M., et al., 7th ed. San Francisco, CA; 2009.
- Kimball's Biology Pages. "Oncogenes" Free full text
- The Nobel Prize in Physiology or Medicine 2002. Illustrated presentation.
- Croce CM (Jan 2008). "Oncogenes and cancer". N Engl J Med. 358 (5): 502–11. doi:10.1056/NEJMra072367. PMID 18234754.
- Yokota J (Mar 2000). "Tumor progression and metastasis". Carcinogenesis. 21 (3): 497–503. doi:10.1093/carcin/21.3.497. PMID 10688870.
- The Nobel Prize in Physiology or Medicine 1989 to J. Michael Bishop and Harold E. Varmus for their discovery of "the cellular origin of retroviral oncogenes".
- The Emperor of All Maladies, Siddhartha Mukherjee, 2011, p. 363
- The Hunting of the Src, G. Steven Martin, Nature Reviews Molecular Cell Biology 2: 467 (2001)
- (A.P. Czernilofsky et al., 1980, Nature Vol 287, pp 198-203).
- Nobel Prize in Physiology or Medicine for 1989 jointly to J. Michael Bishop and Harold E. Varmus for their discovery of "the cellular origin of retroviral oncogenes". Press Release.
- Chapter 20 - NEOPLASMS OF THE THYROID - in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7. 8th edition.
- Todd R, Wong DT (1999). "Oncogenes". Anticancer Res. 19 (6A): 4729–46. PMID 10697588.
- Chial, H (2008). "Proto-oncogenes to Oncogenes to Cancer". Nature Education. 1 (1).
- Negrini M, Ferracin M, Sabbioni S, Croce CM (Jun 2007). "MicroRNAs in human cancer: from research to therapy". J Cell Sci. 120 (Pt 11): 1833–40. doi:10.1242/jcs.03450. PMID 17515481.
- Esquela-Kerscher A, Slack FJ (Apr 2006). "Oncomirs - microRNAs with a role in cancer". Nat Rev Cancer. 6 (4): 259–69. doi:10.1038/nrc1840. PMID 16557279.
- THE Medical Biochemistry Page
- Classification of Oncogene Function
- Press, Richard; Anita Misra; Glenda Gillaspy; David Samols; David A. Goldthwait (June 1, 1989). "Control of the Expression of c-sis mRNA in Human Glioblastoma Cells by Phorbol Ester and Transforming Growth Factor ß1". Cancer Research (49): 2914–2920.
- Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel (May 2004). "Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy". Nature Reviews Cancer. 4 (5): 361–370. doi:10.1038/nrc1360. PMID 15122207.
- Summy, Justin M.; Gallick, GE (1 January 2003). "Src family kinases in tumor progression and metastasis". Cancer and Metastasis Reviews. 22 (4): 337–358. doi:10.1023/A:1023772912750. PMID 12884910.
- Thomas, Sheila M.; Brugge, Joan S. (1 November 1997). "CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES". Annual Review of Cell and Developmental Biology. 13 (1): 513–609. doi:10.1146/annurev.cellbio.13.1.513. PMID 9442882.
- Garnett, Mathew J.; Marais, Richard (1 October 2004). "Guilty as charged: B-RAF is a human oncogene". Cancer Cell. 6 (4): 313–319. doi:10.1016/j.ccr.2004.09.022. PMID 15488754.
- Leicht, D; Vitaly Balan; Alexander Kaplun; Vinita Singh-Gupta; Ludmila Kaplun; Melissa Dobson; Guri Tzivion (August 2007). "Rafkinases: Function, regulation and role in human cancer". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1773 (8): 1196–1212. doi:10.1016/j.bbamcr.2007.05.001.
- Bos, JL (Sep 1, 1989). "ras oncogenes in human cancer: a review". Cancer Research. 49 (17): 4682–9. PMID 2547513.
- Hilgenfeld, Rolf (1 December 1995). "Regulatory GTPases". Current Opinion in Structural Biology. 5 (6): 810–817. doi:10.1016/0959-440X(95)80015-8. PMID 8749370.
- Felsher, Dean W.; Bishop, J.Michael (August 1999). "Reversible Tumorigenesis by MYC in Hematopoietic Lineages". Molecular Cell. 4 (2): 199–207. doi:10.1016/S1097-2765(00)80367-6. PMID 10488335.